Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Summary

The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.

Timeline

Start

2017-12-27

Primary completion

2021-06-30

Completion

2023-06-04

Outcome

Outcome not reported

Stopped: “The study was terminated due to the sponsor's decision to discontinue the clinical trial.”

Drugs

Indications